Compare Alcon AG (ALC) vs Oscar Health Inc (OSCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Oscar Health Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Oscar Health Inc trades at $30.86 (market cap $9.38B). The key difference: Alcon AG is far larger — about 3.5× Oscar Health Inc's market cap, and Alcon AG pays a 0.54% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| ALC | OSCR | |
|---|---|---|
Market Cap | $32.69B | $9.38B |
Sector | Health | Health |
52-Week High | $92.22 | $32.18 |
52-Week Low | $62.02 | $10.85 |
Enterprise Value | $36.28B | $5.01B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Oscar Health (OSCR) trades at $31.44, down 2.3% on the day but showing strong technical momentum with a bullish moving average signal. The company reported a significant Q1 2026 earnings beat with EPS of $2.07 versus $1.21 expected, though full-year 2025 results showed a net loss of $443 million. Revenue growth remains robust, projected to increase from $11.7 billion in 2025 to $13.3 billion in 2026, while operating cash flow improved substantially.
The outlook is mixed: strong revenue growth and positive cash flow support upside potential, but persistent net losses and negative ROE pose fundamental risks. Analyst consensus is cautious with a $22.50 price target below current levels, indicating skepticism about sustainability despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
